Severe Inhibition of Long-Chain Acyl-CoA Enoylhydratase (EC 4.2.1.74) in a Newborn Foal Suffering From Atypical Myopathy

Johannes Sander1,2*, Michael Terhardt1 and Nils Janzen1,2

1 Screening-Labor Hannover, Hanover, Germany, 2 Hanover Medical School, Hanover, Germany

In horses, congenital defects of energy production from long-chain fatty acids have not been described so far. In contrast, inhibition of fatty acid degradation caused by the toxins hypoglycin A and methylenecyclopropylglycine from various maple species are observed frequently. These non-proteinogenic amino acids are passed on placentally to fetuses or with colostrum or milk to newborn foals. Nevertheless, newborn foals become very rarely symptomatic. Vertical transmission apparently is not sufficient to induce clinical disease without a particular genetic constellation being present. One of these rare cases was investigated here using samples from a mare and her foal. Intoxication by hypoglycin A and methylenecyclopropylglycine is also of interest to human pathology, because these toxins have caused fatal poisonings after consumption of certain fruits many times, especially in children. Maple toxins, their metabolites and some short-chain acyl compounds were quantified by ultrahigh-pressure liquid chromatography/tandem mass spectrometry. An comprehensive spectrum of long-chain acylcarnitines was prepared using electrospray ionization tandem mass spectrometry. Organic acids and acylglycines were determined by gas chromatography mass spectrometry. For evaluation, results of other horses poisoned by maple material as well as unaffected control animals were used. In the serum of the foal, hypoglycin A was detected at a low concentration only. Toxin metabolites reached $<3.5\%$ of the mean of a comparison group of horses suffering from atypical myopathy. The spectrum of acylcarnitines indicated enzyme inhibition in short-chain and medium-chain regions typical of acer poisoning, but the measured concentrations did not exceed those previously found in clinically healthy animals after maple consumption. The values were not sufficient to explain the clinical symptoms. In contrast, a remarkably strong enrichment of tetradecenoylcarnitine and hexadecenoylcarnitine was observed. This proves a blockade of the long-chain enoyl-CoA hydratase (EC 4.2.1.74). Vertical transfer of maple toxins to a newborn foal is sufficient for induction of clinical disease only if there is an additional specific reactivity to the active toxins. This was found here in an inhibition of long-chain enoyl-CoA hydratase. Isolated dysfunction of this enzyme has not yet been reported in any species. Further studies are necessary to prove a specific genetic defect.

Keywords: long-chain enoyl-CoA hydratase (EC 4.2.1.74), vertical toxin transmission, hypoglycin A (HGA), methylenecyclopropylglycine (MCPG), atypical myopathy, newborn foal
INTRODUCTION

Several thousands of severe, often lethal cases of atypical myopathy (AM) caused by the ingestion of seeds and seedlings of some Acer species have been observed in horses and other equids, occurring in all age groups from the very young to the very old animals [for review see Votion et al. (1)]. Hypoglycin A (HGA) and methylenecyclopropylglycine (MCPG) are the constituents responsible for this. Newborn foals, however, that do not yet consume green forage themselves and therefore can receive Acer toxins prenatally only via the placenta or postnatally with the milk are apparently very rarely affected by AM.

MCPA-CoA and MCPF-CoA, the active toxins formed from HGA and MCPG, are known to interrupt the energy production from fatty acids and certain amino acids. They inhibit mitochondrial acyl-CoA dehydrogenases and enoyl-CoA hydratases involved in the β-oxidation of fatty acids (2–4). In view of the high postpartum requirement for products of the β-oxidation of fatty acids and amino acid catabolism, one might assume that newborn foals are particularly vulnerable to maple toxins. However, so far, only one case of AM in a foal has been described in the literature (5).

The maple toxins HGA and MCPG have the structure of amino acids. Thus, they can pass through the placenta and enter the fetus like other amino acids. They are also secreted into the milk (6–8). Transplacental transport and secretion of amino acids into the milk, on the other hand, are not primarily achieved by passive diffusion but are the results of active transport. And, in order to trigger toxic effects, HGA, and MCPG must be converted into the active toxins in the foal’s organism after vertical transfer.

Based on the above facts, it must be assumed that placental passage of the toxins into the fetal circulation as well as secretion into the milk are limited. Concentrations sufficient to affect metabolism will therefore not be reached frequently. Furthermore, there is the possibility that the activity of the enzymes necessary for metabolizing maple toxins to MCPA-CoA and MCPF-CoA, cytosolic aminotransferase, and mitochondrial branched-chain dehydrogenase, is comparatively low in the tissues at the end of the fetal period or in the early neonatal period. This would mean that only a small proportion of the toxic amino acids entering the newborn foal’s organism would be converted into active toxins.

On the basis of these considerations, we hypothesize that the low concentrations of active maple toxins to be expected in a foal fed with colostrum or milk will only lead to acute disease if there is a special, possibly genetically determined sensitivity.

Test material received by our laboratory from a mare/foal pair suffering from AM allowed us to investigate some aspects of this hypothesis and to draw tentative conclusions.

MATERIALS AND METHODS

Anamnestic Details

A male foal weighing 50 kg had been nursed by his dam (Iceland pony, 5 years old) until the 7th day of life in a pasture in the neighborhood of Acer pseudoplatanus. When depression, insecure gait, weakness, and finally recumbency were detected in the foal on the 7th day postpartum, in view of the fact that cases of AM had already been confirmed in this pasture, the owner expressed the suspicion that it could be AM. Dam and foal were seen by a veterinarian at the 8th day postpartum. At this time, the dam was described as being weak and stiff but she did not appear to be in acute distress. The foal on the other hand was moribund. Enzyme activities in serum were 45,305 U/L for creatine kinase (CK) in the foal and 19,515 U/L in the dam (ref. <200). Lactate dehydrogenase (LDH) activity in the serum was 2,254 U/L for the foal and 12,833 U/L for the dam (ref. <250). Levels of aspartate aminotransferase (AST) activity in the serum were also greatly elevated (foal 2,656 U/L, dam 16,999 U/L, ref. <50). High concentrations of myoglobin were detected in the urine of the foal (3,990 µg/L) and the dam (1,060 µg/L, ref. <25). The results obtained are compatible with the diagnosis of AM.

The dam recovered within 3 days on a maple free diet of hay and oats. The foal was euthanized because of the severity of symptoms and obviously poor chance of survival. The veterinarian collected samples for diagnostic purposes and requested the toxicological analyses described below.

Materials and Data Available

- Foal: Serum, collected before euthanasia on the 8th day postpartum, urine collected immediately after death
- Dam: Serum and urine, collected on the 8th day postpartum
- Data for comparison were available from the diagnostic workup of our laboratory of 34 AM positive horses and 19 negative controls.

Data of all the horses were used for scientific purposes with owner-informed consent.

Ultrahigh-Performance Liquid Chromatography/Tandem Mass Spectrometry (UPLC-MS/MS)

The quantification of HGA and MCPG plus their metabolites in serum and urine was carried out by UPLC-MS/MS as described in detail earlier (9–12). For all analyses, 25 µL of material were extracted with 300 µL of methanol containing the internal standards. Analysis was performed after butylation. For chromatographic separation 5 µL of the final extracts were injected onto an Acquity UPLC BEH C18 1.7 µm, 2.1 × 50 mm column (Waters). Gradient chromatography was performed using acetonitrile/water modified by 0.1% formic acid and 0.01% trifluoroacetic acid. Quantifications were done on a Xevo TQMS UPLC-MS/MS system (Waters, Eschborn, Germany), calculation of concentrations was conducted with single-point calibration. Concentrations of C4 to C10 acyl conjugates were also determined by this method in order to differentiate branched and unbranched C4 and C5 metabolites. The isomers of 2-MBC

Abbreviations: AM, atypical myopathy; ECH, enoyl-CoA hydratase; FiMS/MS, flow injection-tandem mass spectrometry; HGA, hypoglycin A; MCPA, methylenecyclopropyl acetic acid; MCPF, methylenecyclopropyl formic acid; UPLC-MS/MS, ultra high pressure liquid chromatography-tandem mass spectrometry.
**TABLE 1 | Hypoglycin A and toxin metabolites in serum and urine of the foal and his mare.**

|          | Serum |        |        | Urine |        |        |
|----------|-------|--------|--------|-------|--------|--------|
|          | Foal  | Mare   | Foal   | Mare  | Foal   | Mare   |
|          | nmol/L| % of mean of 34 AM horses | nmol/L | % of mean of 34 AM horses | nmol/mmol creatinine | % mean of 14 AM horses | nmol/mmol creatinine | % mean of 14 AM horses |
| HGA      | 438   | 24.3   | 813    | 45.3  | 68     | 125    | 4.4    | 8.1   |
| MCPA-G   | 6.2   | 3.3    | 48.0   | 25.3  | 969    | 8.4    | 2,550  | 22.2  |
| MCPA-C   | 2.8   | 3.2    | 8.2    | 9.5   | 20.5   | 3.0    | 3.4    | 0.5   |
| MCPF-G   | 1.2   | 1.6    | 30.2   | 39.2  | 57.0   | 1.8    | 1,567  | 49.3  |
| MCPF-C   | 14.5  | 1.2    | 122    | 10.3  | 110    | 1.0    | 194    | 1.8   |

**FIGURE 1 | Hypoglycin A and toxin metabolites measured in the serum of 34 horses suffering from Atypical Myopathy plus the foal (F) and the mare (M).**
appeared in two separate peaks, the values of both isomers were added for quantification.

Flow Injection-Tandem Mass Spectrometry (FI-MS/MS)
A comprehensive range of long-chain acylcarnitines (C12-C18) was quantified using a method originally developed for the study of infant blood (13, 14). This method has been adapted in our laboratory for the analysis of horse serum samples (15). For the study presented here, the serum was spotted onto filter paper (Ahlstrom-Munskjö, Germany). After air-drying, disks of 3.2 mm diameter were punched out (corresponding to 3.5 µl serum) and extracted with 100 µl methanol. After butylation with 50 µL HCl-butanol, drying and resolving the extracts were analyzed using flow injection tandem mass spectrometry without chromatographic separation. Analysis was done on a Waters TQD instrument (Waters, Eschborn, Germany) with an electrospray interface. The instrument was run in the ESI positive mode. Capillary voltage was 2.5 kV. Collision gas (argon) pressure was 2.4 × 10⁻³ mbar. The analysis was done as parent scan, the long chain hydroxylated AC, however, were measured in positive MRM mode because of their very low intensities. MS/MS results were calculated using the Neolynx software 4.1 (Waters), quantifications were done by comparing peak height to the respective d3-carnitine derivatives (C12-C18).

Gas Chromatography Mass Spectrometry (GC-MS)
Organic acids and acylglycines were measured as commissioned service by a commercial human medical laboratory (MVZ Dr. Eberhard & Partner, Dortmund, Germany) who established a spectrum using gas chromatography mass spectrometry as

| TABLE 2 | Concentrations of acylcarnitines found in serum and urine of the foal and the mare. |
|----------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Acyl carnitines | Serum | Mare | Serum | Mare | Serum | Mare |
| µmol/L | % of mean of 34 AM horses | µmol/L | % of mean of 34 AM horses | Mean of 19 neg. controls | µmol/mL | µmol/mL | % of mean of 14 AM horses | % of mean of 14 AM horses |
| Butyryl | 23 | 40.4 | 4.9 | 8.5 | 0.98 | 82.9 | 31.4 | 4.1 | 1.6 | 0.65 |
| Hexanoyl | 3.3 | 45.4 | 2.0 | 27.3 | 0.24 | 3.6 | 6.2 | 0.41 | 0.70 | 0.04 |
| Octanoyl | 0.4 | 32.4 | 0.37 | 30.0 | 0.02 | 1.0 | 13.7 | 0.17 | 2.22 | 0.01 |
| Decenoyl | 0.09 | 11.8 | 0.14 | 28.3 | 0.01 | 0.79 | 11.4 | 0.07 | 0.99 | n.d. |
| Isobutyryl | 8.3 | 129 | 1.3 | 19.8 | 1.5 | 138 | 181 | 7.4 | 9.7 | 2.3 |
| Isovaleryl | 7.0 | 42.8 | 1.1 | 6.5 | 0.31 | 41.8 | 64.8 | 2.7 | 4.2 | 0.28 |
| Methylbutyryl | 4.3 | 31.6 | 1.3 | 9.6 | 0.31 | 47.8 | 58.7 | 6.9 | 8.5 | 0.37 |

| TABLE 3 | Long-chain acylcarnitines, measured by flow-injection MS/MS. |
|----------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Acyl-Carnitines | 21 neg. controls | Level nmol/L | % of mean of 34 AM horses | Level nmol/L | % of mean of 34 AM horses | Level nmol/L | % of mean of 34 AM horses |
| Dodecanoyl, C12 | 99.8 | 114 | 86.9 | 132 | 101 |
| Dodecenoyl, C12:1 | 15.7 | 75 | 93.5 | 14 | 175 |
| Myristoyl, C14 | 27.6 | 52.8 | 103 | 30.4 | 59.6 |
| Hydroxymyristoyl, C14-OH | 4.7 | 2.8 | 17.0 | 5.8 | 35.2 |
| Tetradecenoyl C14:1 | 14.1 | 155 | 262 | 13 | 22.1 |
| Tetradecadienoyl C14:2 | 6.2 | 16 | 111 | 6.4 | 44.6 |
| Palmitoyl, C16 | 43.3 | 61.9 | 33.5 | 42.4 | 22.9 |
| Hydroxypalmitoyl, C16-OH | 3.6 | 4.3 | 23.0 | 4.9 | 26.1 |
| Palmitoleoyl, C16:1 | 17.7 | 103 | 133 | 12 | 15.4 |
| Hydroxypalmitoleoyl, C16:1-OH | 5.7 | 5.4 | 23.4 | 5.2 | 22.5 |
| Stearyl, C18 | 24.0 | 34.8 | 49.5 | 23.7 | 33.8 |
| Hydroxyoctadecenoyl, C18-OH | 4.4 | 11.3 | 164 | 9 | 130 |
| Oleoyl, C18:1 | 37.1 | 68.5 | 42.0 | 31.7 | 19.4 |
| Hydroxyoctoyl, C18:1-OH | 4.4 | 6.9 | 41.3 | 6.4 | 38.3 |
| Linoleyl, C18:2 | 10.2 | 7.3 | 19.3 | 11.5 | 30.4 |
| C18:2-OH | 6.5 | 10 | 64.3 | 17 | 109 |
described by Hoffmann et al. (16). The methods are used there as quality-controlled routine diagnostic procedures in human medicine.

RESULTS

Toxins and Toxin Metabolites
Concentrations of HGA and toxin metabolites are shown in Table 1. In the serum of the foal, HGA, not present in body fluids of unaffected horses, reached only 53.3% of the level of the mare. However, the foal excreted unmetabolized HGA to a considerably higher extent than the mare. With 68 nmol HGA/mmol creatinine, the foal reached 125% of the mean of positive controls. Non-metabolized MCPG, which we had confirmed in other cases of maple poisoning of horses (17) was not detected in quantifiable concentrations. In serum, the metabolites MCPA-glycine and MCPA-carnitine derived from HGA as well as MCPF-carnitine and -glycine derived from MCPG, not detectable in unaffected horses, reached only a few percent of the mean of the group. This is clearly visible in Figure 1. The low levels corresponded to a very low excretion of toxin metabolites as compared to other AM horses (Table 1).

Medium-Chain Acyl Carnitines in Serum and Urine
A high accumulation in the serum of the mare and the foal of butyrylcarnitine, a derivative of butyryl-CoA, which is metabolized by both medium-chain acyl-CoA dehydrogenase (MCAD, OMIM 607008) and short-chain acyl-CoA dehydrogenase (SCAD, OMIM 606885) was found (Table 2). The high concentrations indicate a pronounced inhibition of both enzymes especially in the foal. Increased concentrations in the serum of the foal and the mare alike of octanoylcarnitine and decenoylcarnitine are further indicators of inhibition of the MCAD enzyme. The branched-chain isobutyrylcarnitine, however, which indicates dysfunction of the isobutyryl-CoA dehydrogenase (OMIM 611283), was measured in increased concentrations in the serum of the foal only.

In the group of acylcarnitines with five carbon atoms high values for isovalerylcarnitine and 2-methylbutyrylcarnitine were measured especially in the serum of the foal indicating that he had a particularly pronounced inhibition of isovaleryl-CoA dehydrogenase (OMIM 607036) and 2-methylbutyryl-CoA dehydrogenase (OMIM 610006), which have functions in the degradation of leucine and isoleucine, respectively. Values for the unbranched valerylcarnitine were within the normal range in both animals.

Long-Chain Acylcarnitines in the Serum
In the range of long-chain acylcarnitines with chain lengths of 12–18 C-atoms, again, the values measured in the foal and the mare exceeded those of the negative controls (Table 3). This was true for both the saturated compounds that are products of the first step of the β-oxidation spiral as well as for the products of

---

**FIGURE 2** Ratios of C14:1 to other acylcarnitines in the group of horses suffering from Atypical Myopathy including the foal (F) and the mare (M).
the second step, the monounsaturated acylarnitines. However, while values close to or below the mean of the comparison group were found for the saturated compounds, values for the unsaturated compounds C 14:1 and C16:1 were particularly high in the serum of the foal, amounting to 262 and 133% of the means of the comparison group, respectively. The particularly strong inhibition of the second reaction step of β-oxidation in the serum of the foal, amounting to 262 and 133% of the mean of the comparison group, respectively. The particularly strong inhibition of the second reaction step of β-oxidation in the foal becomes clear when the concentrations of C14:1 are put in relation to that of C14-OH as shown in Figure 2. While a ratio of 51.7/1 is calculated for the foal, the ratio for the mare is only 2.2/1.

**Organic Acids and Acylglycines in Urine**

The analysis of the urine for organic acids provided results that confirmed and expanded those obtained by serum samples. In their entirety, they are a sign for a massively disturbed energy production from fatty acids and amino acids, a fact that is also underlined by the extremely high excretion of lactate in the foal. The results of the urine tests not only confirmed the impairment of the dehydrogenases and enoylhydratases shown for serum but also revealed various secondary metabolic disorders e.g., the accumulation of pyroglutamic acid as a sign of malfunction of the glutamyl cycle (Table 4).

While inhibition of the SCAD enzyme (OMIM 201470) in the mare as well as in the foal is indicated by high values obtained for ethylmalonic acid and 2-ethyl-3-hydroxypropionic acid, inhibition of the short/branched-chain acyl-CoA dehydrogenase enzyme (OMIM 600301), also called 2-methylbutyryl-CoA dehydrogenase, is proven by elevated excretion of 2-ethylhydracrylic acid (2-ethyl-3-hydroxypropionic acid) (18, 19). The pronounced excretion of the saturated dicarboxylic acids adipic and suberic acids and the ketone body 3-hydroxybutyric acid are clear indicators for the inhibition of the MCAD enzyme. Metabolites such as methylsuccinic acid or glutaric acid are typical markers of disorders in the metabolism of various amino acids.

Metabolic inhibition also led, as expected, to a greatly increased excretion of the corresponding acylglycines. The excretion of the acylglycines exceeded that of the corresponding carnitine compounds by two to three powers of ten. As a consequence of a nutrition from vegetable food, a large excretion of hippuric acid and phenylpropionylglycine (Table 5) was observed in the dam but not in the foal who did not eat plant material.

**DISCUSSION**

The foal developed the full clinical picture of AM. The diagnosis is supported by strongly elevated values for muscle enzymes such as CK, LDH and by the excretion of myoglobin. Nevertheless, the biochemical findings suggest marked differences from other cases of AM. First, the very low serum level of HGA measured at the peak of clinical disease is noteworthy. It reached only 24.3% of the mean of the values found in the horses with AM used for comparison. The low level of HGA is further demonstrated by comparison with samples obtained from clinically healthy individuals. In a previous study (19), we found HGA levels that were higher than in the foal in 9 out of 12 clinically unsuspicious horses who had shared pasture with horses suffering from AM. A mean HGA level of 771 nmol (range: 268–2,327) was found in this group. The value of 438 nmol/L measured in the foal examined here represents only 56.8% of this mean. This corresponds in magnitude to values in 2 clinically healthy co-grazing horses observed by Baise et al. (20). Also noteworthy are the very low values found for MCPA and MCPF conjugates, as shown in Table 1. The concentrations of MCPA carnitine and.

---

**Table 4** | Excretion of organic acids in urine showing organaciduria which is severe in the foal, less pronounced in the mare, values in mg/g creatinine.

| Acid                  | Foal   | Mare  | Control |
|-----------------------|--------|-------|---------|
| lactic                | 3,800  | 17.5  | 4.9     |
| glycolic              | 41     | 11.6  | 5.6     |
| 3-hydroxypropionic    | 1.8    | 0     | 0.6     |
| 3-hydroxybutyric      | 128    | 18    | 1.6     |
| 3-hydroxyisovaleric   | 66     | 1.2   | 0.3     |
| 2-methyl-3-hydroxybutyric | 9.5    | 14.5  | 10.8    |
| 3-hydroxy-isovaleric  | 6.4    | 8.4   | 7.5     |
| methylmalonic         | 0.4    | 0.9   | 1.6     |
| 2-ethyl-3-hydroxypropionic | 33    | 41    | 1.4     |
| 4-Hydroxybutyric      | 7.8    | 2     | 0.5     |
| ethylmalonic          | 47     | 36    | 1       |
| methylsuccinic        | 33     | 30    | 7.6     |
| glycercic             | 53     | 2.8   | 2.2     |
| fumaric               | 2.5    | 0.5   | 0.6     |
| mevalonic             | 0      | 0     | 1       |
| glutaric              | 13.5   | 2     | 0.3     |
| 3-methylglutaric      | 0      | 0     | 0.2     |
| 3-methylglutaconic    | 1.6    | 3     | 0       |
| adipic                | 106    | 9.7   | 0.4     |
| pyroglutamic          | 131    | 8.6   | 17      |
| 2-hydroxy glutaric    | 114    | 31    | 3.4     |
| 3-hydroxy glutaric    | 6.2    | 3.4   | 1.6     |
| 3-hydroxy-3-methylglutaric | 3.1    | 0     | 4.8     |
| 2-ketoglutaric        | 4.6    | 3.2   | 0       |
| N-acetylaspartic      | 2.1    | 4.4   | 0.2     |
| suberic               | 76     | 4.7   | 1       |
| sebacic               | 0      | 1.3   | 0.4     |

**Table 5** | Renal excretion of acylglycines and hippuric acid.

| Excretion<sup>a</sup> | Foal | Dam | Control |
|-----------------------|------|-----|---------|
| Isovalerylglycine      | 25.7 | 40.6| 0.3     |
| Hexanoylglycine        | 23.6 | 29.5| 0.1     |
| Methylcrotonylglycine  | 2.1  | 8.3 | 0.1     |
| Tigliylglycine         | 0.2  | 1.2 | <0.1    |
| Phenylpropionylglycine | 0.5  | 15  | <0.1    |
| Hippuric acid          | 2.8  | 44.3| 0.5     |

<sup>a</sup>Excretion measured in µmol/mmol creatinine.
The enzyme is, at least in humans, integrated into the mitochondrial chain enoyl-CoA hydratase (OMIM 609015, EC 4.2.1.74). The function of the enzyme responsible for this hydration step, long-chain acylcarnitines makes it evident that the β-oxidation of the long-chain fatty acids was blocked at the stage of hydration to the C14-OH and C16-OH compounds. This indicates an extensive loss of function of the enzyme responsible for this hydration step, long-chain enoyl-CoA hydratase (OMIM 609015, EC 4.2.1.74). The enzyme is, at least in humans, integrated into the mitochondrial trifunctional protein which also harbors the β-hydroxy-acyl-CoA dehydrogenase and long-chain thiolase. However, there was no indication that these activities were negatively affected neither in the mare nor the foal.

An isolated defect of the long-chain ECH as a congenital disease has not yet been described for any species. Whether a genetic defect could underlie the present case would have had to be proven by appropriate genetic studies. Unfortunately, no suitable tissue was available. Thus, it must be left to the investigation of further cases to confirm this speculation.

REFERENCES

1. Votion DM, François AC, Kruse C, Renaud B, Farinelle A, Bouquieaux MC, et al. Answers to the frequently asked questions regarding horse feeding and management practices to reduce the risk of atypical myopathy. Animals. (2020) 10:365. doi: 10.3390/ani10020365
2. Kean EA. Selective inhibition of acyl-CoA dehydrogenases by a metabolite of hypoglycin. Biochim Biophys Acta. (1976) 422:8–14. doi: 10.1016/0005-2744(76)90003-6
3. Li D, Agnihotri G, Dakoji S, Zhou HQ, Liu HW. The toxicity of methylenecyclopropylglycine: studies of the inhibitory effects of (methylenecyclopropyl)formyl-CoA on enzymes involved in fatty acid metabolism and the molecular basis of its inactivation of enoyl-CoA hydratases. J Am Chem Soc. (1999) 121:9034–42. doi: 10.1021/ja991908w
4. Westermann CM, de Sain-van der Velden MG, van der Kolk JH, Berger R, Wijnberg ID, Koeman JP, et al. Equine biochemical multiple acyl-CoA dehydrogenase deficiency (MADD) as a cause of rhabdomyolysis. Mol Genet Metab. (2007) 91:362–9. doi: 10.1016/j.ymgme.2007.04.010
5. Karlíková R, Široká J, Mech M, Friedecký D, Janečková H, Mádrová L, et al. Newborn foal with atypical myopathy. J Vet Intern Med. (2018) 32:1768–72. PMID: 30216546. doi: 10.1111/jvim.15236
6. Sander J, Terhardt M, Janzen N. Detection of maple toxins in mare’s milk. J Vet Intern Med. (2020) 35:606–9. doi: 10.1111/jvim.16004
7. Renaud B, François AC, Boemer F, Kruse C, Stern D, Piot A, et al. Grazing mares on pasture with sycamore maples: a potential threat to suckling foals and food safety through milk contamination. Animals. (2021) 11:87. doi: 10.3390/ani11100087
8. González-Medina S, Bevin W, AlzolaDomingo R, Chang Y-M, Piercy RJ. Hypoglycin A absorption in sheep without concurrent clinical or biochemical evidence of disease. J Vet Intern Med. (2021) 35:1170–6. doi: 10.1111/jvim.16077
9. Sander J, Terhardt M, Sander S, Aboling S, Janzen N. A new method for quantifying causative and diagnostic markers of methylenecyclopropylglycine poisoning. Toxicol Rep. (2019) 6:803–8. doi: 10.1016/j.toxrep.2019.08.002
10. Sander J, Terhardt M, Sander S, Janzen N. Quantification of methylenecyclopropyl compounds and acyl conjugates by UPLC-MS/MS in the study of the biochemical effects of the ingestion of canned ackee (Blighia sapida) and lychee (Litchi chinensis). J Agric Food Chem. (2017) 65:2603–8. doi: 10.1021/acs.jafc.7b00224
11. Sander J, Cavalleri JM, Terhardt M, Bochnia M, Zeyner A, Zuraw A, et al. Rapid diagnosis of hypoglycin A intoxication in atypical myopathy of horses. J Vet Diagn Invest. (2016) 28:98–104. doi: 10.1177/1040638715624736
12. Sander J, Terhardt M, Sander S, Janzen N. Quantification of hypoglycin A as butyl ester. J Chromatogr B Analyt Technol Biomed Life Sci. (2016) 1029-1030:169–73. doi: 10.1016/j.chroma.2016.07.005
13. Chace DH, DiPerna JC, Naylor EW. Laboratory integration and utilization of tandem mass spectrometry in neonatal screening: a model for clinical mass spectrometry in the next millennium. Acta Paediatr Suppl. (1999) 88:45–7. doi: 10.1111/j.1651-2227.1999.tb01156.x

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS

JS was the principal investigator and conducted the conceptualization and experimental design. MT performed the analyses and was responsible for quality control. NJ supervised the interpretation of the study results and reviewed the draft. All authors contributed to the article and approved the submitted version.
14. Rashed MS, Rahbeeni Z, Ozand PT. Application of electrospray tandem mass spectrometry to neonatal screening. *Semin Perinatol.* (1999) 23:183–93. doi: 10.1016/S0146-0005(99)80058-0

15. Sander J, Terhardt M, Sander S, Janzen N. Use of a standard newborn screening test for the rapid diagnosis of inhibited β-Oxidation in atypical myopathy in horses. *J Equine Vet Sci.* (2018) 67:71–4. doi: 10.1016/j.jevs.2018.03.010

16. Hoffmann G, Aramaki S, Blum-Hoffmann E, Niyhan WL, Sweetman L. Quantitative analysis for organic acids in biological samples: batch isolation followed by gas chromatographic-mass spectrometric analysis. *Clin Chem.* (1989) 35:587–95. doi: 10.1093/clinchem/35.4.587

17. Bochnia M, Ziegler J, Sander J, Uhlig A, Schaefer S, Vollstedt S, et al. Hypoglycin A content in blood and urine discriminates horses with atypical myopathy from clinically normal horses grazing on the same pasture. *PLoS One.* (2015) 10:e0136785. doi: 10.1371/journal.pone.0136785

18. Korman SH, Andersen BS, Zeharia A, Gutman A, Boneh A, Pitt J. 2-ethylhydracrylic aciduria in short/branched-chain acyl-CoA dehydrogenase deficiency: application to diagnosis and implications for the R-pathway of isoleucine oxidation. *Clin Chem.* (2005) 51:610–7. doi: 10.1373/clinchem.2004.043265

19. Sass JO, Ensenaer R, Röschingher RW, Reich H, Steuerwald U, Schirrmacher O, et al. 2-Methylbutyryl-coenzyme A dehydrogenase deficiency: functional and molecular studies on a defect in isoleucine catabolism. *Mol Genet Metab.* (2007) 93:30–5. doi: 10.1016/j.ymgme.2007.09.002

20. Raise E, Habyarimana JA, Amory H, Boemer F, Douny C, Gustin P, et al. Samaras and seedlings of Acer pseudoplatanus are potential sources of hypoglycin A intoxication in atypical myopathy without necessarily inducing clinical signs. *Equine Vet J.* (2016) 48:414–7. doi: 10.1111/evj.12499

21. Boutron A, Acquaviva C, Vianney-Saban C. Comprehensive cDNA study and quantitative analysis of mutant HADHA and HADHB transcripts in a French cohort of 52 patients with mitochondrial trifunctional protein deficiency. *Mol Genet Metab.* (2011) 103:341–8. doi: 10.1016/j.mgen.2011.04.006

22. Sander J, Sander S, Steuerwald U, Janzen N, Peter M, Wanders RJA, et al. Neonatal screening for defects of the mitochondrial trifunctional protein. *Mol Genet Metab.* (2005) 85:108–14. doi: 10.1016/j.ymgme.2005.02.002

23. Van Calcar SC, Sowa M, Rohr F, Beazer J, Setlock T, Weihe TU, et al. Nutrition management guideline for very-long chain acyl-CoA dehydrogenase deficiency (VLCAD): an evidence- and consensus-based approach. *Mol Genet Metab.* (2020) 131:23–37. doi: 10.1016/j.ymgme.2020.10.001

24. Lepori V Mühlhauser F, Sewell AC, Jagannathan V, Janzen N, Rosati M, et al. Nonsense variant in the ACADVL gene in German hunting terriers with exercise induced metabolic myopathy. *G3 (Bethesda).* (2018) 8:1545–54. doi: 10.1534/g3.118.200084

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Sander, Terhardt and Janzen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.